Nicotinic acid and clofibrate derivatives are the main triglyceride-metabolism-affecting drugs. Nicotinic acid and its derivatives block adipose tissue lipolysis thus reducing the FFA flux of free fatty acids to the liver and the synthesis of very-low-density lipoproteins (VLDL). VLDL removal rate is also enhanced. Disturbing side effects (mostly flushing) limit the use of this compound. Clofibrate and its derivatives decrease the synthesis of VLDL and increase their catabolism. Lipoprotein lipase activity as well as VLDL fractional catabolic rate are increased by fibrates. Triglyceride synthesis is also reduced.